Posts From November, 2019

Pravin U. Dugel MD: Economic Value of Anti–Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States

Karen Mulligan, PhD1,6; Seth A. Seabury, PhD2,6; Pravin U. Dugel, MD3,4; et al Key Points Question  How much economic value do anti–vascular endothelial growth factor (anti-VEGF) treatments generate for patients with wet age-related macular degeneration and society in the United States? Findings  In this economic evaluation study, visual acuity improvement associated with anti-VEGF treatments generated $5.1 billion to $8.2 billion in… Read More »

Dr. Neal Palejwala on AZTV’s Health Matters for Diabetes Awareness Month

Retinal Consultants of Arizona’s Dr. Neal Palejwala was featured on AZTV’s Health Matters segment to discuss diabetes awareness month and the relationship to eye healthcare. Dr. Palejwala discussed the world-class care of the retina practice as well as the Retinal Research Institute – the nation’s leading, independent eye care clinical trial program taking place in… Read More »

Pravin U. Dugel, MD: Conversations in Age-Related Macular Degeneration

Neovascular AMD Pravin U. Dugel, MD What up-and-coming therapies for wet AMD are you most excited about and why? The therapies currently being investigated for neovascular age-related macular degeneration (nvAMD) can be stratified into 3 silos: better short-term efficacy, better long-term efficacy, and increased durability. The majority of drugs in the pipeline have focused on… Read More »